PDCD1 and intrahepatic cholangiocarcinoma: Based on the above research results, we conducted a multicenter retrospective study to evaluate the efficacy, safety, and prognostic factors for survival of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line systemic therapy for patients with advanced ICC in a real-world study.